BioNTech SE (BNTX)
64.34
+0.20 +0.31%
NASDAQ
Jul 2, 14:44
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 122.36M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -0.9402 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -213.12M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 78.88% |
| Profit Margin (Quarterly) | -193.0% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 14.59B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 119.39 |
| PE Ratio | -- |
| Price to Book Value | 29.52 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.1487 |
| Free Cash Flow (Quarterly) | -69.64M |
| Return on Equity | Upgrade |
View All BNTX News
News
-
WireHeadlineTime (ET)
-
Yahoo07/02 12:34
-
Yahoo07/02 11:05
-
MT Newswires07/02 10:24
-
Yahoo07/02 09:32
-
Yahoo07/02 09:09
-
Yahoo07/02 08:42
-
SA Breaking News07/02 08:17
-
MT Newswires07/02 06:34
-
Yahoo07/02 06:21
-
Yahoo07/02 06:17
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 03/31/2021 | Earnings | BioNTech SE Fourth Quarter Earnings Results for 2020 |
| 03/31/2021 | Misc | BioNTech SE Fourth Quarter Earnings Conference Call for 2020 |
| 11/10/2020 | Earnings | BioNTech SE Third Quarter Earnings for 2020 Release |
| 11/10/2020 | Misc | BioNTech SE Third Quarter Earnings Conference Call for 2020 |
| 08/11/2020 | Earnings | BioNTech SE Second Quarter Earnings for 2020 Release |
| 08/11/2020 | Misc | BioNTech SE Second Quarter Earnings Conference Call for 2020 |
| 05/15/2020 | Misc | BioNTech SE Annual General Meeting for 2019 |
| 05/12/2020 | Earnings | BioNTech SE First Quarter Earnings for 2020 Release |
| 05/12/2020 | Misc | BioNTech SE First Quarter Earnings Conference Call for 2020 |
| 03/31/2020 | Earnings | BioNTech SE Fourth Quarter Earnings for 2019 Release |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.biontech.de
- Investor Relations URL: N/A
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: N/A
- Next Earnings Release: Aug. 11, 2020
- Last Earnings Release: May. 12, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab and does not yet have any commercialized medicines.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 64.34 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| GERM | ETFMG Treatments Testing and Adv ETF | 4.57% |
| CNCR | Loncar Cancer Immunotherapy ETF | 3.71% |
| GDNA | Goldman Sachs Human Evolution ETF | 1.84% |
| IDNA | iShares Genomics Immnlgy & Hlthcr ETF | 1.73% |
| FPXE | First Trust IPOX Europe Equity Opps ETF | 1.22% |
| BBC | Virtus LifeSci Biotech Clinical Trls ETF | 0.91% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BNTX Tweets Stocktwits
Advertisement
